The price advantage of Apelvis in 2024

Alpelisib (Alpelisib) is a targeted treatment drug for breast cancer. It is a PI3K inhibitor that can specifically inhibit the activity of PI3Kα (PIK3CA) and block the PI3K/AKT/mTOR signaling pathway. This signaling pathway is abnormally activated in many cancers and is closely related to the growth, proliferation and survival of tumor cells.

Apelixis is mainly used to treat hormone receptor-positive, human epidermal growth factor receptor2-negative advanced or metastatic breast cancer, especially patients withPIK3CA mutations and those who have developed resistance to endocrine therapy. This makes apelvis an effective treatment option for these specific patient groups. The results of multiple clinical trials have confirmed the significant efficacy of Apelvis in the treatment of breast cancer. The results of these trials show that apelvis can significantly extend patients' progression-free survival and improve their quality of life.

The original drug of Apelvis has not yet been launched in China, so it is not included in the scope of medical insurance. Its domestic selling price is temporarily unknown. In overseas markets, Apelix’s original drug is available in a variety of versions, including European and Indian versions. Among them, the European version contains 150mg*56 tablets per box, and its price may be as high as more than 40,000 yuan; while the Indian version contains 150mg*28 tablets per box, and the price is relatively affordable, about more than 5,000 yuan. Please note that these prices may change due to exchange rate fluctuations.

In addition, generic drugs of Apelvis have been released in overseas markets, and their drug ingredients are basically the same as the original drug. For example, the generic Apelvis drug produced by a pharmaceutical factory in Laos has a specification of 150mg*28 tablets per box, and the price is about more than 2,000 yuan. However, the price may fluctuate due to the exchange rate. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.